These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2197582)

  • 1. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion.
    Ludwig CU; Ludwig-Hagemann R; Obrist R; Obrecht JP; Holdener EE; Sutter-Melde C
    Onkologie; 1990 Apr; 13(2):117-22. PubMed ID: 2197582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
    Deprés-Brummer P; Levi F; Di Palma M; Beliard A; Lebon P; Marion S; Jasmin C; Misset JL
    J Immunother (1991); 1991 Dec; 10(6):440-7. PubMed ID: 1768678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.
    Bukowski RM; Murthy S; Sergi J; Budd GT; McKeever S; Medendorp SV; Tubbs R; Gibson V; Finke J
    J Biol Response Mod; 1990 Dec; 9(6):538-45. PubMed ID: 2074440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days.
    Dorr RT; Salmon SE; Robertone A; Bonnem E
    J Interferon Res; 1988 Dec; 8(6):717-25. PubMed ID: 3230330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
    Jurincic-Winkler C; Horlbeck R; Klippel KF
    Wien Klin Wochenschr; 1993; 105(10):271-6. PubMed ID: 8517056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
    J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
    Wadler S; Goldman M; Lyver A; Wiernik PH
    Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
    Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
    J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
    Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
    Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
    Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
    J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.